Complex and prolonged hypercoagulability in coronavirus disease 2019 intensive care unit patients: A thromboelastographic study.


Journal

Australian critical care : official journal of the Confederation of Australian Critical Care Nurses
ISSN: 1036-7314
Titre abrégé: Aust Crit Care
Pays: Australia
ID NLM: 9207852

Informations de publication

Date de publication:
Mar 2021
Historique:
received: 01 09 2020
revised: 24 10 2020
accepted: 22 11 2020
pubmed: 30 1 2021
medline: 27 3 2021
entrez: 29 1 2021
Statut: ppublish

Résumé

A high number of thrombotic complications have been reported in critically ill patients with coronavirus disease 2019 (COVID-19) and appear to be related to a hypercoagulable state. Evidence regarding detection, management, and monitoring of COVID-19-associated coagulopathy is still missing. We propose to describe the thrombus viscoelastic properties to investigate the mechanisms of hypercoagulability in patients with COVID-19. Thromboelastography (TEG) was performed in 24 consecutive patients admitted to a single intensive care unit for COVID-19 pneumonia, and 10 had a second TEG before being discharged alive from the intensive care unit. Compared with a group of 20 healthy participants, patients with COVID-19 had significantly decreased values of reaction time, coagulation time, and lysis index and increased values of α angle, maximum amplitude, clot strength, and coagulation index. Velocity curves were consistent with increased generation of thrombin. These values persisted in surviving patients despite their good clinical course. In patients with COVID-19, TEG demonstrates a complex and prolonged hypercoagulable state including fast initiation of coagulation and clot reinforcement, low fibrinolysis, high potential of thrombin generation, and high fibrinogen and platelet contribution. The antithrombotic strategy in patients with COVID-19 during intensive care hospitalisation and after discharge should be investigated in further studies.

Sections du résumé

BACKGROUND BACKGROUND
A high number of thrombotic complications have been reported in critically ill patients with coronavirus disease 2019 (COVID-19) and appear to be related to a hypercoagulable state. Evidence regarding detection, management, and monitoring of COVID-19-associated coagulopathy is still missing. We propose to describe the thrombus viscoelastic properties to investigate the mechanisms of hypercoagulability in patients with COVID-19.
METHODS METHODS
Thromboelastography (TEG) was performed in 24 consecutive patients admitted to a single intensive care unit for COVID-19 pneumonia, and 10 had a second TEG before being discharged alive from the intensive care unit.
RESULTS RESULTS
Compared with a group of 20 healthy participants, patients with COVID-19 had significantly decreased values of reaction time, coagulation time, and lysis index and increased values of α angle, maximum amplitude, clot strength, and coagulation index. Velocity curves were consistent with increased generation of thrombin. These values persisted in surviving patients despite their good clinical course.
DISCUSSION CONCLUSIONS
In patients with COVID-19, TEG demonstrates a complex and prolonged hypercoagulable state including fast initiation of coagulation and clot reinforcement, low fibrinolysis, high potential of thrombin generation, and high fibrinogen and platelet contribution. The antithrombotic strategy in patients with COVID-19 during intensive care hospitalisation and after discharge should be investigated in further studies.

Identifiants

pubmed: 33509706
pii: S1036-7314(20)30348-9
doi: 10.1016/j.aucc.2020.11.007
pmc: PMC7835109
pii:
doi:

Types de publication

Journal Article

Langues

eng

Pagination

160-166

Informations de copyright

Copyright © 2020 Australian College of Critical Care Nurses Ltd. Published by Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest On behalf of all the authors, the corresponding author states that there is no conflict of interest.

Auteurs

Pierre-Yves Cordier (PY)

Intensive Care Unit, Laveran Military Teaching Hospital, 34 Boulevard Laveran, 13384, Marseille, France. Electronic address: py.cordier@icloud.com.

Candice Pierrou (C)

Intensive Care Unit, Laveran Military Teaching Hospital, 34 Boulevard Laveran, 13384, Marseille, France.

Alexandre Noel (A)

Intensive Care Unit, Laveran Military Teaching Hospital, 34 Boulevard Laveran, 13384, Marseille, France.

Raphaël Paris (R)

Intensive Care Unit, Laveran Military Teaching Hospital, 34 Boulevard Laveran, 13384, Marseille, France.

Eliott Gaudray (E)

Intensive Care Unit, Laveran Military Teaching Hospital, 34 Boulevard Laveran, 13384, Marseille, France.

Edouard Martin (E)

Intensive Care Unit, Laveran Military Teaching Hospital, 34 Boulevard Laveran, 13384, Marseille, France.

Claire Contargyris (C)

Intensive Care Unit, Laveran Military Teaching Hospital, 34 Boulevard Laveran, 13384, Marseille, France.

Frédérik Bélot-De Saint Léger (F)

Intensive Care Unit, Laveran Military Teaching Hospital, 34 Boulevard Laveran, 13384, Marseille, France.

Arthur Lyochon (A)

Intensive Care Unit, Laveran Military Teaching Hospital, 34 Boulevard Laveran, 13384, Marseille, France.

Hélène Astier (H)

Medical Biology Laboratory, Laveran Military Teaching Hospital, 34 Boulevard Laveran, 13384, Marseille, France.

Florian Desmots (F)

Radiology Department, Laveran Military Teaching Hospital, 34 Boulevard Laveran, 13384, Marseille, France.

Hélène Savini (H)

Infectious Diseases Unit, Laveran Military Teaching Hospital, 34 Boulevard Laveran, 13384, Marseille, France.

Corinne Surcouf (C)

Medical Biology Laboratory, Laveran Military Teaching Hospital, 34 Boulevard Laveran, 13384, Marseille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH